Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment

Fubing Wang

Status: Enrolling

Conditions: Primary Liver Cancer; HBV

Treatments: Diagnostic Test: HBV DNA Sequencing

Study type: Observational

Funder types: Other

Identifiers

NCT05677724

20220929

Details and patient eligibility

About

In summary, with the help of single-cell sequencing technology, this study aims to focus on elucidating the influence of HBV-induced hepatocellular carcinoma cell metabolic changes on microenvironment remodeling. With the help of hepatocellular carcinoma microenvironment changes, this study provide a more accurate diagnosis and treatment method for HBV-induced hepatocellular carcinoma.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with primary liver cancer (hepatocellular carcinoma (HCC)), with evidence of histological or cytological diagnosis, or with HCC meeting conventional clinical diagnostic criteria.
• Both sexes, aged 18-80 years old
• The results of HBVDNA test were in line with the inclusion criteria
• The patient had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST V1.1)
• Agreed to comply with the study protocol for treatment and follow-up, agreed to provide clinicopathological and follow-up data required by the study, and agreed to use the study data for subsequent research and product development

Exclusion criteria

• Other malignant tumors;
• Patients with severe organic diseases do not meet the requirements of infectious liver cancer in this study;
• Suffering from mental illness cannot guarantee the compliance of this study;
• Previous recipients of any cell or organ transplantation;
• Received local regional liver therapy (including various ablations, percutaneous ethanol or acetic acid injections, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization plus embolization) within 14 days prior to study treatment initiation.

Trial design

20 participants in 5 patient groups

Group 1

Description:

HBV DNA(\>20000IU/mL)

Treatment:

Diagnostic Test: HBV DNA Sequencing

Group 2

Description:

HBV DNA(\>2000IU/mL)

Treatment:

Diagnostic Test: HBV DNA Sequencing

Group 3

Description:

HBV DNA(10-2000IU/mL)

Treatment:

Diagnostic Test: HBV DNA Sequencing

Group 4

Description:

HBV DNA(=\<10IU/mL)

Treatment:

Diagnostic Test: HBV DNA Sequencing

Group 5

Description:

HBV DNA(0 IU/mL)

Treatment:

Diagnostic Test: HBV DNA Sequencing